DOI: https://doi.org/10.22141/2224-1485.2.46.2016.74491

Sartan potential in treatment of arterial hypertension and comorbid conditions: choice of olmersartan

Ye.H. Nesukai

Abstract


The articleis devoted to the useof olmesartanforthe treatment of hypertensionand comorbidconditions, the data of clinicalstudiesof this drug.Discusses the combinationof olmesartanwith drugsof other groups.Alsothe article talksabout angioprotective andcerebroprotectivepropertiesof olmesartan.

References


Березин А.Е. Клиническая эффективность и безопасность применения олмесартана — нового антагониста рецепторов к ангиотензину II у пациентов с артериальной гипертензией // Укр. мед. часопис. — 2009. — № 4 (72). — C. 25-30.

Горбась І.М. Контроль артеріальної гіпертензії серед населення: стан проблеми за даними епідеміологічних досліджень // Укр. кард. журн. — 2007. — № 2. — С. 21-25.

Сиренко Ю.Н., Рековец О.Л. Роль олмесартана в лечении артериальной гипертензии // Артериальная гипертензия. — 2009. — № 2 (4).

Стрес і хвороби системи кровообігу / За ред. В.М. Коваленка, В.М. Корнацької. — 2015. — 354 с.

Agata J., Ura N., Yoshida H. et al. Olmesartan is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme // Hypertens. Res. — 2006. — Vol. 29. — P. 865-874.

Ball K. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist Olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension // J. Hypertens. — 2001. — Vol. 19 (suppl. 2). — P. 153.

Bramlage Р., Zemmrich С., Gansz А. et al. Daytime Systolic Ambulatory Blood Pressure With a Two-Step Switch From Candesartan to Olmesartan Monotherapy and the Fixed-Dose Combination of Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL-2) // J. Clin. Hypertens (Greenwich). — 2014. — Vol. 16. — P. 41-46.

Brunner H.R. Clinical efficacy and tolerability of olmesartan // Clin. Ther. — 2004. — Vol. 26 (suppl. A). — P. A28-A32.

Brunner H.R., Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist // J. Hypertens. — 2001. — Vol. 19 (suppl. 1). — P. S15-S20.

Brunner H.R., Stumpe K.O., Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan сilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension // Clin. Drug Investig. — 2003. — Vol. 23. — P. 419-430.

Burnier M. Managing 'resistance': is adherence a target for treatment? // Curr. Opin. Nephrol. Hypertens. — 2014. — Vol. 23 (5). — P. 439-43.

Burnier M., Brunner H. Angiotensin II receptor antagonists // Lancet. — 2000. — Vol. 355. — P. 637-645.

Cal L.A., Maso L.D., Caielli P. et al. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence // Blood Press. — 2011. — Vol. 20 (6). — P. 376-82.

Crackower M.A., Sarao R., Oudit G.Y. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function // Nature. — 2002. — Vol. 417. — P. 822-828.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Daikuhara Н., Fukunaga К., Ohshima Т. Difference in the effects of switching from Candesartan to Olmesartan orTelmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study // Drug Design, Development and Therapy. — 2014. — Vol. 8. — P. 219-226.

Danser A.H.J., Tom B., de Vries R. et al. L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition // Br. J. Pharmacol. — 2000. — Vol. 131. — P. 195-202.

Donoghue M., Hsieh F., Baronas E. et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 // Circ. Res. — 2000. — Vol. 87. — P. el-e9.

Ferreira A.J., Santos R.A.S., Almeida A.P. Angiotensin- (1–7):

cardioprotective effect in myocardial ischemia reperfiision // Hypertension. — 2001. — Vol. 38. — P. 665-668.

Fliser D., Buchholz K., Haller H. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation // Circulation. — 2004. — Vol. 110. — P. 1103-1107.

Fliser D., Wagner K., Loss A. et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes // J. Am. Soc. Nephrol. — 2005. — V. 16. — P. 1135-1140.

Fukuda M., YamanakaT., Mizuno M. et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis // J. Hypertens. — 2008. — Vol. 26 (3). — P. 583-588.

Giles T.D., Oparil S., Silfani T.N. et al. Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension // J. Clin. Hypertension. — 2007. — Vol. 9, № 3. — Р. 187-195.

Giles T.D., Robinson T.D. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension // Am. J. Hypertens. — 2004. — Vol. 17 (8). — P. 690-695.

Heagerty A.M., Mallion J.M. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials // Drugs Aging. — 2009. — Vol. 26 (1). — P. 61-76.

Hermida R.C., Ayala D.E., Vojon A. et al. Influence of circadian time of hypertension treatment on cardiovascular risk: result of the MAPEC study // Chronobiol. Int. — 2010. — Vol. 27. — P. 1629-1651.

Hirohata A., Yamamoto K., Miyoshi T. et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial // Atherosclerosis. — 2012. — Vol. 220 (1). — P. 134-138.

Hirohata A., Yamamoto K., Miyoshi T. et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial // J. Am. Coll. Cardiol. — 2010. — Vol. 55 (10). — P. 976-82.

Ichikawa S., Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients // Hypertens Res. — 2001. — Vol. 24. — P. 641-646.

Ikeda H., Hamamoto Y., Honjo S. et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes // Diabetes Res. Clin. Pract. — 2009. — Vol. 83 (l). — P. 117-118.

Jung O. et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis // J. Hypertens. — 2013. — Vol. 31 (4). — P. 766-74.

Kamikawa S., Usui S., Ogawa H. et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients // Heart Vessels. — 2011. — Vol. 26 (4). — P. 408-13.

Kannel W.B., Wolf P.A., McGee D.L. et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study // JAMA. — 1981. — Vol. 245. — P. 1225-1229.

Kario K., Hoshide S., Shimizu M. et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study // J. Hypertens. — 2010. — Vol. 28 (7). — P. 1574-1583.

Kario K., Jishikawa J., Pickering T.G. et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients // Hypertens Res. — 2006. — Vol. 29. — 581-587.

Kato J., Yokota N., Tamaki N. et al. Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity // J. Am. Soc. Hypertens. — 2012. — Vol. 6 (6). — P. 393-8.

Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data // Lancet. — 2005. — Vol. 365. — P. 217-223.

Kiya Y., Miura S., Fujino M. et al. Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan // Clin. Exp. Hypertens. — 2010. — Vol. 32 (2). — P. 129-136.

Kurata A., Nishizawa H., Kihara S. et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation // Kidney Int. — 2006. — Vol. 70. — P. 1717-1724.

Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. — 2002. — V. 360. — P. 1903-1913.

Loot A.E., Roks A.J., Henning R.H. et al. Angiotenisn-(1–7) attenuates the development of heart failure after myocardial infarction in rats // Circulation. — 2002. — Vol. 105. — P. 1548-1550.

Lorenzen J.M., Neuhoeffer H., David S. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension — results from the EUTOPIA trial // Atherosclerosis. — 2010. — Vol. 209 (1). — P. 184-8.

Mancia G., Fagard R., Narkiewicz K. et al. Task Force Members. 2013 ESH 'ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. — 2013. — Vol. 31 (7). — P. 1281-1357.

Matsumoto S., Shimodozono M., Miyata R. et al. The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke // Int. J. Neurosci. — 2010. — P. 120 (5). — P. 372-80.

Matsumoto S., Shimodozono M., Miyata R. et al. Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke // Hypertens Res. — 2009. — Vol. 32 (11). — P. 1015-1021.

Matsumoto S., Shimodozono M., Miyata R. et al. Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients // Brain Inj. — 2009. — Vol. 23 (13-14). — P. 1065-72.

Misuno M., Sada T., Kato M. et al. Renoprotective effects of blockade of angiotensin II ATI receptors in an animal model of type 2 diabetes // Hypertens Res. — 2002. — Vol. 25. — P. 271-278.

Miura S., Fujino M., Hanzawa H. et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor // J. Biol. Chem. — 2006. — Vol. 281. — P. 19288-19295.

Miyashita Y., Saiki A., Endo K. et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension // J. Atheroscler. Thromb. — 2009. — Vol. 16 (5). — P. 621-6.

Mori H., Yamamoto H., Ukai H. et al. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study // Hypertension Research. — 2013. — Vol. 36. — P. 202-207.

Nagata R., Kawabe K., Ikeda K. Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension // J. Stroke Cerebrovasc. Dis. — 2010. — Vol. 19 (3). — P. 236-40.

Nakayama S., Watada H., Mita T. et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension // Hypertens. Res. — 2008. — Vol. 31 (1). — P. 7-13.

Nishimura Y., Ito T., Saavedra J.M. Angiotensin II ATi blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats // Stroke. — 2000. — Vol. 31. — P. 2478-2486.

Ohishi M., Takeya Y., Tatara Y. et al. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: High-dose ARB with ACE inhibitor (Hawaii) study // Hypertension Research. — 2010. — Vol. 33. — P. 1150-1154.

Oparil S., Williams D., Chrysant S.G. et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension // J. Clin. Hypertens. — 2001. — Vol. 3 (5). — P. 283-291.

Rudziftski W., Swiat M., Tomaszewski M. et al. Cerebral hemodynamics and investigations of cerebral blood flow regulation // Nucl. Med. Rev. Cent. East Eur. — 2007. — Vol. 10. — P. 29-42.

Scott L.J., McCormack P.L. Olmesartan medoxomil: a review of its use in the management of hypertension // Drugs. — 2008. — Vol. 68 (9). — P. 1239-72.

Shimada K., Ogihara T., Saruta T. et al. REZALT Study Group. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study // Clin. Ther. — 2010. — Vol. 32 (5). — P. 861-881.

Takeda S., Sato N., Takeuchi D. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling // Hypertension. — 2009. — Vol. 54 (6). — P. 1345-52.

Takiguchi S., Ayaori M., Uto-Kondo H. et al. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase // Hypertens. Res. — 2011. — Vol. 34 (6). — P. 686-92.

Tsuda M., Iwai M., Li J.M. et al. Inhibitory effects of ATI receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress // Hypertension. — 2005. — Vol. 45. —

P. 545-551.

Turner A.J., Tipnis S.R., Guy J.L. et al. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a monologue of angiotensin-converting enzyme insensitive to ACE inhibitors // Can. J. Physiol. Pharmacol. — 2002. — Vol. 80. — P. 346-353.

Walters P.E., Gaspari T.A., Widdop R.E. Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats // Hypertension. — 2005. — Vol. 45. — P. 960-966.

Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial // Lancet. — 2004. — Vol. 363. — P. 2049-2051.

Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? // Clin. Ther. — 2004. — V. 24 (suppl. А). — P. A21-A27.

Wolf-Maier K., Cooper R.S., Banegas J.R. et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States // JAMA. — 2003. — Vol. 289. — P. 2363-2369.

Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet. — 2004. — Vol. 364. — P. 937-952.

Zannad F., Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies // Fundam. Clin. Pharmacol. — 2007. — Vol. 21. — P. 181-190.

Zemmrich C., Luders S., Gansz A. et al. Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1) // Clin. Hypertens. — 2013. — doi: 10.1111/jch. 12202.




Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта